Subscribe to RSS
Histomorphological and Morphometric Evaluation of Microvessel Density in Nodal Non-Hodgkin Lymphoma Using CD34 and CD105
Background Expression of angiogenic markers determined by microvessel density (MVD) could be used as a reliable predictor of prognosis and as a potential target for antiangiogenic therapy in different categories of non-Hodgkin lymphoma (NHL).
Aims The aim of this study was to evaluate MVD using immunohistochemical methods and computer-assisted quantitative image analysis in nodal NHL patients and compare CD34 and CD105 expression in lymph nodes of NHL patients.
Materials and Methods The present study was conducted on 60 lymph node biopsies received in the Department of Pathology at our tertiary care center for histopathological examination. Representative paraffin-embedded tissue sections were stained with hematoxylin and eosin along with immunohistochemical stains for CD34 and CD105. MVDs were analyzed at 400× using automated image analyzer by two investigators independently.
Statistical Analysis Data were calculated, tabulated, and statistically analyzed using SPSS (Statistical Package for Social Studies) statistical program version 18. The values entered were mean of morphometric parameters. In all tests, p-values below 0.05 were regarded as significant.
Results MVD was determined by CD34 and CD105 antibody highly correlated with different categories of NHL. Higher MVD was observed in cases of aggressive NHL as compared with indolent NHL and the difference was statistically significantly. MVD using CD105 was correlated more strongly as compared to CD34 with different categories of NHL.
Conclusion The present study concluded that NHL exhibits potent angiogenic activity that increased significantly with increasing aggressiveness. The study also demonstrated that CD105 is more specific than CD34 as a marker of neoangiogenesis in NHL.
22 May 2021 (online)
© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Chang KL, Arber DA, Weiss LM. Lymph nodes and spleen. In: DeLellis RA, Frable WT, Li Volsi VA, Wick MR, eds. Silverberg’s Principles and Practice of Surgical Pathology and Cytopathology. 5th edition. Vol. 1, Cambridge (UK):. Cambridge University Press 2015; 688-812
- 2 Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59 (03) 728-733
- 3 Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leuk Lymphoma 2003; 44 (12) 2089-2093
- 4 Asahara T, Murohara T, Sullivan A. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275 (53/02) 964-967
- 5 Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203
- 6 Hamada J, Cavanaugh PG, Miki K, Nicolson GL. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component C3b. Cancer Res 1993; 53 (18) 4418-4423
- 7 Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103 (02) 159-165
- 8 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407 (68/01) 249-257
- 9 Weidner N, Folkman J, Pozza F. et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84 (24) 1875-1887
- 10 Mezei T, Horváth E, Turcu M, Gurzu S, Raica M, Jung I. Microvascular density in non-Hodgkin B-cell lymphomas measured using digital morphometry. Rom J Morphol Embryol 2012; 53 (01) 67-71
- 11 Aggarwal D, Srivastava G, Gupta R, Pant L, Krishan G, Singh S. Angiogenesis in Non-Hodgkin’s lymphoma: an intercategory comparison of microvessel density. ISRN Haematol. 2012. 943089
- 12 Ruan J, Hyjek E, Kermani P. et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin’s lymphoma. Clin Cancer Res 2006; 12 (19) 5622-5631
- 13 Duşe AO, Ceauşu RA, Cîmpean AM, Ioniţă H, Raica M, Gaje P. Heterogeneity of malignant non-Hodgkin lymphoma-associated blood vessels. Rom J Morphol Embryol 2012; 53 (04) 985-988
- 14 Ribatti D, Vacca A, Marzullo A. et al. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Int J Cancer 2000; 85 (02) 171-175
- 15 Ridell B, Norrby K. Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS 2001; 109 (01) 66-72
- 16 Arias V, Soares FA. Vascular density (tumor angiogenesis) in non-Hodgkin’s lymphomas and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 2000; 40 (01/02) 157-166
- 17 Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56 (01/02) 45-53
- 18 Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005; 17 (06) 611-616
- 19 Tzankov A, Heiss S, Ebner S. et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol 2007; 60 (05) 476-482
- 20 Mazur G, Wróbel T, Dziegiel P, Jeleń M, Kuliczkowski K, Zabel M. Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin’s lymphoma. Folia Histochem Cytobiol 2004; 42 (04) 241-243
- 21 Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143 (02) 401-409
- 22 Netto GC, Bleil CB, Hilbig A, Coutinho LM. Immunohistochemical evaluation of the microvascular density through the expression of TGF-β(CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 2008; 28 (01) 17-23
- 23 Näyhä V, Viitanen T, Stenbäck F. Altered extent, pattern and characteristics of microvascular density are indicators of neoplastic progression in the endometrium. Int J Cancer 2005; 115 (06) 975-980
- 24 Laitakari J, Näyhä V, Stenbäck F. Size, shape, structure, and direction of angiogenesis in laryngeal tumour development. J Clin Pathol 2004; 57 (04) 394-401
- 25 Kumar S, Ghellal A, Li C. et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59 (04) 856-861
- 26 Yao Y, Pan Y, Chen J, Sun X, Qiu Y, Ding Y. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci 2007; 37 (01) 39-48
- 27 Tanaka F, Otake Y, Yanagihara K. et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7 (11) 3410-3415
- 28 Sugita Y, Takase Y, Mori D, Tokunaga O, Nakashima A, Shigemori M. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival. J Neurooncol 2007; 82 (03) 249-256
- 29 Akagi K, Ikeda Y, Sumiyoshi Y. et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002; 131 (Suppl. 01) S109-S113
- 30 Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 2006; 95 (12) 1683-1688